Literature DB >> 7589057

Pharmacokinetics of fluconazole after oral administration in children with human immunodeficiency virus infection.

M C Nahata1, M T Brady.   

Abstract

The objective of this study was to determine the pharmacokinetics of fluconazole after oral administration in children with human immunodeficiency virus (HIV) infection. After an overnight fast, a single dose of either 2 mg.kg-1 or 8 mg.kg-1 was administered in a suspension; five children received 2 mg.kg-1 and four 8 mg.kg-1 (ages 5-13 years). Blood samples were collected at various times on day 1, and once daily on days 2-7 after the dose. Fluconazole serum concentrations were measured by gas chromatography. At the dose of 2 mg.kg-1, the Cmax, AUC (0-infinity), and t1/2 ranged from 2.3-4.4 micrograms.ml-1, 84.9-136 micrograms.h.ml-1, and 19.8-34.8 h, respectively. At the dose of 8 mg.kg-1 the Cmax, AUC (0-infinity), and t1/2 ranged from 5.4-12.1 micrograms.ml-1, 330-684 micrograms h.ml-1, and 25.6-42.3 h, respectively. When compared with published data in healthy adults, fluconazole achieved similar serum concentrations in the present group of children, indicating a nearly complete degree of absorption.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589057     DOI: 10.1007/BF00198314

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

Review 1.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

2.  Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men.

Authors:  W T Hughes; W Kennedy; J L Shenep; P M Flynn; S V Hetherington; G Fullen; D J Lancaster; D S Stein; S Palte; D Rosenbaum
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

3.  Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome.

Authors:  A M Sugar; C Saunders
Journal:  Am J Med       Date:  1988-10       Impact factor: 4.965

4.  Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients.

Authors:  J J Stern; B J Hartman; P Sharkey; V Rowland; K E Squires; H W Murray; J R Graybill
Journal:  Am J Med       Date:  1988-10       Impact factor: 4.965

5.  Virus-associated colitis in homosexual men: two case reports.

Authors:  D Guttman; A Raymond; A Gelb; H Ehya; U Mather; D Mildvan; I Spigland
Journal:  Am J Gastroenterol       Date:  1983-03       Impact factor: 10.864

6.  Erratic zidovudine bioavailability in HIV seropositive patients.

Authors:  K A Macnab; M J Gill; L R Sutherland; N De Boer Visser; D Church
Journal:  J Antimicrob Chemother       Date:  1993-03       Impact factor: 5.790

Review 7.  Clinical pharmacokinetics of fluconazole.

Authors:  D Debruyne; J P Ryckelynck
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

8.  Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.

Authors:  W Hughes; G Leoung; F Kramer; S A Bozzette; S Safrin; P Frame; N Clumeck; H Masur; D Lancaster; C Chan
Journal:  N Engl J Med       Date:  1993-05-27       Impact factor: 91.245

9.  Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease.

Authors:  C V Fletcher; F S Rhame; C C Beatty; M Simpson; H H Balfour
Journal:  Pharmacotherapy       Date:  1992       Impact factor: 4.705

10.  Enteropathy associated with the acquired immunodeficiency syndrome.

Authors:  D P Kotler; H P Gaetz; M Lange; E B Klein; P R Holt
Journal:  Ann Intern Med       Date:  1984-10       Impact factor: 25.391

View more
  5 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

2.  Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.

Authors:  Gopal Krishna; Angela Sansone-Parsons; Monika Martinho; Bhavna Kantesaria; Lisa Pedicone
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

3.  Potency and Preclinical Evidence of Synergy of Oral Azole Drugs and Miltefosine in an Ex Vivo Model of Leishmania (Viannia) panamensis Infection.

Authors:  Olga Lucía Fernández; Mariana Rosales-Chilama; Natali Quintero; Bruno L Travi; Dawn M Wetzel; María Adelaida Gómez; Nancy Gore Saravia
Journal:  Antimicrob Agents Chemother       Date:  2021-10-25       Impact factor: 5.938

4.  Developmental changes of fluconazole clearance in neonates and infants in relation to ontogeny of glomerular filtration rate: literature review and data analysis.

Authors:  Kazutoshi Murakoso; Ryoichi Minagawa; Hirotoshi Echizen
Journal:  J Pharm Health Care Sci       Date:  2018-03-20

Review 5.  Clinical Pharmacokinetics of Triazoles in Pediatric Patients.

Authors:  Didi Bury; Wim J E Tissing; Eline W Muilwijk; Tom F W Wolfs; Roger J Brüggemann
Journal:  Clin Pharmacokinet       Date:  2021-05-18       Impact factor: 5.577

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.